ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CRON
TRLV (58) RGC (38) TLRY (20) OBIO (36) ⌘ Pro Terminal →

Cronos Group Inc. Common Share (CRON) — RQD Stock Rating Cockpit

$3.30 -1.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.28

Cronos Group Inc. Common Share (CRON) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $1.24B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRON Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $3.30 (-1.79% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #285 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRON compare to TRLV and RGC in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRON?
▼

Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.28 (-0.51%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (13)SEC (11)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-3% Base Target
$4 Bull$3 Base$3 Bear
📬 FREE CRON RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRON)Realized 20D OHLCV Swing Band: ±5.3%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY CRON SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (25% of score)

20D Institutional Volume Accumulation (±5.3% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($149.0K FCF) & 42.8% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$3.21+1.2% Next Q
Q2 (-2Q)
46
Grade D$3.25+1.8% Next Q
Q3 (-1Q)
48
Grade D$3.31-0.3% Next Q
Current
51
Grade D$3.30-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRON Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRON currently carries a cautious 51/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.30) and Max Pain ($3.47) forces dealer call-delta covering toward $3.79.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
5530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
15.20>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE77% OF RANGE
L: $2$3.30H: $4
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (43% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on CRON

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

-4.5% ROIC with 42.8% gross margin and 0.01% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 15.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (47)

18/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CRON
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRON)

  • ✓Walkthrough of CRON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CRON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.53%🛡️ HOLDING TREND SUPPORT
2026-11-02O $3.35H $3.36L $3.30C $3.30VOL 666.4K
RES: $3.43SUP: $3.27SMA50: $3.30SMA200: $2.86
$3.69$3.37$3.05$2.74$2.42RES $3.43SUP $3.27$3.302026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRON Butterfly Map → + Track CRON →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +24.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRON)

Health Care Rank #285 of 1016 ⚔️ TRLV vs CRON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRON vs. TRLV, RGC, TLRY, OBIO)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cronos Group Inc. Common Share (CRON) ranks #285 by composite RQD confidence (51/100, grade D) and #334 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, CRON leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CRON at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRON ACTIVE
Cronos Group Inc. Common Share
D 51/100 — 42.8% -4.5% -1.79% $1.24B Benchmark Subject
TRLV
Trulieve Cannabis Corp. Subordinate Voting Shares
D+ 58/100 — 60.2% 12.8% -3.02% $2.04B /trlv-vs-cron →
RGC
Regencell Bioscience Holdings Limited
D- 38/100 — — — -2.19% $3.40B /rgc-vs-cron →
TLRY
Tilray Brands Inc.
E 20/100 — 28.4% -3.9% -4.17% $390.2M /tlry-vs-cron →
OBIO
Orchestra BioMed Holdings Inc.
D- 36/100 — 96.0% -35.0% -2.96% $366.0M /obio-vs-cron →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001656472

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cronos Group Inc. Common Share (CRON) reported GAAP revenue of $146.6M (+24.6% vs. FY2024 revenue of $117.6M , and +68.0% cumulative change since FY2023) , GAAP net income of -$2.9M, operating cash flow of $25.9M, and free cash flow of $149.0K (-97.7% YoY). On the balance sheet, CRON closed FY2025 with $1.20B in total assets against $0 in total debt (Altman Z-Score: 15.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $146.6M -$2.9M $25.9M $149.0K $1.20B —
FY2024 (FY) 2024-12-31 $117.6M $40.0M $18.8M $6.4M $1.17B —
FY2023 (FY) 2023-12-31 $87.2M -$73.9M -$42.8M -$42.8M — —

3. CRON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $3.30 (-1.79% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #285 in composite RQD confidence.

How does CRON compare to TRLV and RGC in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRON?

Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRON trading relative to its 50-day, 200-day, and 52-week technical levels?

CRON last traded at $3.30 (-1.79% on volume of 1,091,082 shares), positioning the stock 0.00% above its 50-day simple moving average ($3.30) and +15.38% above its 200-day simple moving average ($2.86). Across its 52-week range of $2.28 to $3.61, CRON sits at the 76.7% percentile with a 14-day RSI of 55.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.3% ($3.13 to $3.47).

CRON Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CRON stock right now?

Cronos Group Inc. Common Share (CRON) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.

What is CRON's 12-month price target and RQD AI Jury consensus?

CRON's 12-month base price target is $3.2 (range $2.5 to $3.79), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CRON RQD Cockpit CRON 12M Forecast CRON Earnings & Move CRON Dividends & DRIP CRON Insiders & 13F CRON Whale Options CRON Profit Sankey CRON News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRON — Cronos Group Inc. Common Share: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CRON carries an RQD Score of 51 and a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC -4.5%; FCF yield 0.01%), Whale 13F Flow at 13/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 15.2; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is insider conviction, and the cash engine is also weak given negative ROIC and a near-zero FCF yield. The balance-sheet pillar is comparatively stronger on the forensic metrics provided. For a prospective investor, the rating points to limited earnings-based upside support today, with the strongest supportive evidence coming from the balance-sheet and institutional-flow pillars rather than from operating returns. Valuation tradeoffs cannot be assessed precisely because P/E and EV/EBITDA are not available in source data.

Business

Cronos Group Inc. Common Share (CRON) is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile does not describe its specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $146.6M for FY 2025. Beyond sector, industry, and exchange, further business detail is not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$146.6M$-17.4M$-2.9MN/A$0.1M$791.8MN/A
FY 2024$117.6M$-76.5M$40.0MN/A$6.4M$858.8MN/A
FY 2023$87.2M$-84.8M$-73.9MN/A$-42.8MN/AN/A

Per the SEC financials, revenue grew from $87.2M in FY 2023 to $146.6M in FY 2025, while operating income remained negative in all three periods. Per the market data, the gross margin is 42.8%, the operating margin is -11.9%, and the net margin is -2%, with ROIC at -4.5%. Per the Roarable RQD rating, the Altman Z-Score is 15.2 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. Reported cash was $791.8M at FY 2025, down from $858.8M at FY 2024.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. The only sector-level context available is the Health Care classification and the Medicinal Chemicals and Botanical Products industry, with a beta of 1.0 per the market data.

Open Questions

  • What are the company's specific products, customers, and revenue drivers behind the reported revenue growth?
  • What are the P/E (TTM), forward P/E, and EV/EBITDA, and how do they compare with peers?
  • What drove the FY 2025 net loss of $-2.9M and the swing from FY 2024 net income of $40.0M?
  • What is the company's debt position, given that debt is reported as N/A across all periods?
  • What do the institutional 13F and insider Form 4 filings specifically show behind the whale-flow and insider-conviction pillar scores?

CRON Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cronos Group Inc. Common Share (CRON) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRON Debate Forum (3) ↓
🟢 CATALYST Yahoo Finance • 5d ago
3 Canadian Penny Stocks With P E Under 18

AI is soaking up massive amounts of capital right now, with Meta’s recent US$25 billion share sale reportedly drawing demand about five times larger than the deal size. That kind of appetite for growth stories can pull a

Read Full Source ↗
🟡 MARKET WIRE Yahoo Finance • 7d ago
3 Canadian Penny Stocks With Net Margins Over 39%

Energy prices are back in the spotlight as the Bank of Canada signals a possible rate hike to keep fuel driven inflation from spilling into everything from groceries to rent. Higher borrowing costs can punish heavily ind

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRON Bull vs. Bear Conversation Board — What's Your Call at $3.30?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRON 🐻 50% BEARISH CONVICTION
1. Pick Your Side on CRON:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.63 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CRON (D • RQD 51/100) a Buy at $3.36?

Welcome to the CRON (Cronos Group Inc. Common Share) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.76 (-17.9%)
Spot @ $3.36

Pump the brakes on CRON — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CRON, but look at what you are paying: current EV/EBITDA multiples with 42.8% gross margins. Unless Cronos Group Inc. Common Share expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.07 (+21.1%)
Spot @ $3.36

CRON cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CRON, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $3.36 (52-wk range $2.28 - $3.61), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%